Edgewise Therapeutics, Inc. financial data

Symbol
EWTX on Nasdaq
Location
Boulder, CO
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2395% % -14%
Debt-to-equity 5% % 10%
Return On Equity -31% % -15%
Return On Assets -29% % -15%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 105,868,434 shares 12%
Common Stock, Shares, Outstanding 105,761,949 shares 12%
Entity Public Float $1,400,000,000 USD 263%
Common Stock, Value, Issued $10,000 USD 11%
Weighted Average Number of Shares Outstanding, Basic 105,492,779 shares 12%
Weighted Average Number of Shares Outstanding, Diluted 105,492,779 shares 12%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $144,165,000 USD 22%
General and Administrative Expense $36,802,000 USD 27%
Operating Income (Loss) $180,967,000 USD -23%
Net Income (Loss) Attributable to Parent $157,241,000 USD -27%
Earnings Per Share, Basic -1 USD/shares -6%
Earnings Per Share, Diluted -1 USD/shares -6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $46,003,000 USD 2.7%
Assets, Current $573,900,000 USD 15%
Property, Plant and Equipment, Net $8,129,000 USD -18%
Operating Lease, Right-of-Use Asset $1,437,000 USD -11%
Other Assets, Noncurrent $695,000 USD
Assets $583,466,000 USD 14%
Accounts Payable, Current $6,157,000 USD 9%
Employee-related Liabilities, Current $7,998,000 USD 29%
Accrued Liabilities, Current $6,483,000 USD 5.7%
Liabilities, Current $21,646,000 USD 14%
Operating Lease, Liability, Noncurrent $3,173,000 USD -8%
Liabilities $24,819,000 USD 11%
Accumulated Other Comprehensive Income (Loss), Net of Tax $701,000 USD -33%
Retained Earnings (Accumulated Deficit) $496,155,000 USD -46%
Stockholders' Equity Attributable to Parent $558,647,000 USD 14%
Liabilities and Equity $583,466,000 USD 14%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $37,866,000 USD -32%
Net Cash Provided by (Used in) Financing Activities $2,223,000 USD -99%
Net Cash Provided by (Used in) Investing Activities $43,898,000 USD
Common Stock, Shares Authorized 1,000,000,000 shares 0%
Common Stock, Shares, Issued 105,761,949 shares 12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,255,000 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $46,003,000 USD 2.7%
Deferred Tax Assets, Valuation Allowance $111,692,000 USD 60%
Deferred Tax Assets, Gross $111,692,000 USD 60%
Depreciation $2,109,000 USD 3.9%
Payments to Acquire Property, Plant, and Equipment $297,000 USD -93%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $157,591,000 USD -28%
Property, Plant and Equipment, Gross $14,373,000 USD 2.1%
Operating Lease, Liability, Current $1,008,000 USD 1.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $1,054,091,000 USD 28%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $32,613,000 USD 47%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%